Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 899 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of the Cervix Clear all

Conditions: Cervical Cancer Screening
Interventions: eHealth Promotora, eHealth Healthy Nutrition; Behavioral
Lead sponsor: Florida A&M University; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Cervical Cancer, HPV Infection
Interventions: Qualitative Interview, Virtual Visit Standard Instructions, Virtual Visit Standard Instructions + In-Person Registration Navigation; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Cancer, Metastatic Cervical Cancer
Interventions: Balstilimab (BAL), Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Uterine Cervical Neoplasms, HPV Testing, Pap Smear
Interventions: Human papillomavirus Self-collection, Usual Care; Other
Lead sponsor: University of Arizona; Other
Eligibility: 30 Years to 64 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Cervical Cancer, Cervical Carcinoma
Interventions: pembrolizumab, olaparib; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Miami, Florida • Plantation, Florida

Conditions: Advanced Cancer, Cervical Cancer
Interventions: AGEN2034; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more

Conditions: Cervical Cancer, HPV
Interventions: Blood Assayed for CTCs; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Uterine Cervical Neoplasms
Interventions: Bintrafusp alfa; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas • Stanford, California + 8 more

Conditions: Cervical Cancer
Interventions: Patient Survey, Provider Survey; Other
Lead sponsor: Sarasota Memorial Health Care System; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Cervical Cancer
Interventions: educational intervention, questionnaire administration, study of socioeconomic and demographic variables, survey administration; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Gestational Trophoblastic Disease
Interventions: Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List; Behavioral
Lead sponsor: Ira Winer; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cervical Cancer
Interventions: Intervention, Active control; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 341 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Cervix Cancer
Interventions: Topotecan, Cisplatin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Cervical Cancer, Prostate Cancer, Colon Cancer, Lung Cancer
Interventions: Color-coded materials, Academic detailing, Standard support, No academic detailing; Other
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 30 Years to 89 Years
Enrollment: 218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: New York, New York

Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions: VGX-3100, Matched Placebo, CELLECTRA™-5PSP; Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Tucson, Arizona • Danbury, Connecticut • Newark, Delaware + 24 more

Conditions: Hodgkin's Disease, Cervical Cancer, Breast Cancer, Lymphoma
Interventions: Telephone Survey; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 14 Years and older · Female only
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions: Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 345
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 266 more

Conditions: Cervical Cancer
Interventions: Patient-Collected Cervical Pap Smear; Device
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Metastatic Carcinoma of the Cervix
Interventions: Nirapaib; Drug
Lead sponsor: Michelle S Ludwig; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions: PET-CT, MR-PET; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cervical Cancer
Interventions: Single Photon Emission Computed Tomography, Intraoperative Lymphatic Mapping; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometrial Cancer, Cervical Cancer
Interventions: IC Green; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 7
States / cities: Mobile, Alabama • Indianapolis, Indiana • Edgewood, Kentucky + 4 more

Conditions: Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
Interventions: Drug Product De-TIL-0255; Biological
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Buffalo, New York • Pittsburgh, Pennsylvania

Conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more

Search by objective public record fields.

Effectiveness of an eHealth Intervention for Uptake of Cervical Cancer Screening in Hispanic Women

Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Human Papillomavirus (HPV) Self-Sampling Options to Promote Equity

Pembrolizumab and Olaparib in Cervical Cancer Patients

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

CTCs in Cervix Cancer

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

A Review of Cervical Cancer Screening Practices in Women Age >65

Written Educational Information and Phone Calls in Increasing Follow-Up Care in Hispanic Women With Abnormal Pap Smears

ASk Questions in GYnecologic Oncology (ASQ-GYO)

Intervention to Improve Follow-up of Abnormal Pap Test

Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer

Improving Compliance With Medical Testing Guidelines

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Psychosocial Impact of Cancer-Related Female Infertility

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Clinician-Collected Versus Patient-Collected Cervical Pap Smears

Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix

PET-CT vs. Integrated MR-PET Scanning of GYN Cancers

Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer

Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging

A Study of DeTIL-0255 in Adults With Advanced Malignancies

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)